The FDA just escalated its campaign against compounded GLP-1 medications. On April 30, 2026, the agency proposed formally excluding semaglutide, tirzepatide, and liraglutide from the 503B outsourcing facility bulk drug substances list—a move that, if finalized, would permanently prohibit large-scale compounding of these medications regardless of future market conditions. A public comment period runs through June 29, 2026.
If you're a man currently using or considering compounded semaglutide, here's what you need to know.
What Changed
During the 2022–2024 GLP-1 shortage, compounding pharmacies were legally permitted to produce versions of semaglutide and tirzepatide under specific FDA frameworks. When Novo Nordisk reported that branded semaglutide supply had stabilized in early 2025, those allowances began tightening. The FDA gave 503B outsourcing facilities until May 2025 to wind down semaglutide injection production.
Now the agency is moving to make this permanent. The proposed rule would prevent outsourcing facilities from ever compounding these agents from bulk drug substances—even if future shortages occur.
Is Compounded Semaglutide Currently Legal?
The answer is nuanced and depends on the type of pharmacy:
503A pharmacies (traditional compounding pharmacies) can still compound semaglutide on a patient-specific basis, meaning each prescription is individualized based on a valid patient-provider relationship. This remains legal under Section 503A of the Federal Food, Drug, and Cosmetic Act, subject to state regulations.
503B outsourcing facilities (which compound in larger batches without patient-specific prescriptions) are facing the most immediate restrictions. The proposed rule, if finalized, would shut this pathway down entirely for GLP-1 medications.
Safety Concerns: Real vs. Overstated
The FDA's concerns aren't baseless. Compounded medications are not evaluated for safety, efficacy, or quality in the same way as FDA-approved drugs. Potency can vary between batches. Some samples have been found to contain impurities, inconsistent concentrations, or in the worst cases, semaglutide salt forms (like semaglutide sodium) that are chemically different from the FDA-approved base form.
However, not all compounding is equal. State-licensed, PCAB-accredited compounding pharmacies operating under strict sterile manufacturing protocols produce consistently safe products. The FDA's enforcement actions have primarily targeted unlicensed or non-compliant operations, not the entire compounding industry.
What This Means for Your Treatment
If you're currently on compounded semaglutide from a 503A pharmacy with a valid prescription and a legitimate patient-provider relationship, your treatment is not immediately affected by the proposed rule. However, the regulatory landscape is shifting and availability may change.
Options to discuss with your provider:
1. Continue compounded therapy through a licensed 503A pharmacy while it remains available. Verify your pharmacy's credentials.
2. Transition to brand-name Wegovy or Zepbound. Manufacturer savings cards can reduce costs to $25/month with commercial insurance. The self-pay gap remains significant ($1,000+/month).
3. Consider oral Foundayo (orforglipron), the newly approved oral GLP-1. Self-pay starts at $149/month—comparable to some compounded options.
4. Explore Sesame Care or similar platforms that offer transparent pricing on FDA-approved, brand-name GLP-1 medications.
Providers Still Offering Compounded GLP-1s
These telehealth providers currently offer compounded GLP-1 medications through licensed pharmacies:
Compounded medications are not FDA-approved. FDA does not evaluate compounded products for safety, effectiveness, or quality.
Compounded medications are not FDA-approved. FDA does not evaluate compounded products for safety, effectiveness, or quality.
Compounded medications are not FDA-approved. FDA does not evaluate compounded products for safety, effectiveness, or quality.
Brand-Name Only Option
The Bottom Line
Compounded semaglutide is still available through legitimate channels in 2026, but the window is narrowing. The FDA's proposed rule signals a clear direction: large-scale compounding of GLP-1 medications will not have a regulatory future. Men currently benefiting from compounded therapy should work with their providers to develop transition plans while maintaining uninterrupted treatment.